Adipotide OXY-ADI peptide (10 mg) OxyPharma

Catalogue entry: Adipotide OXY-ADI peptide (10 mg) OxyPharma. Labelled content: 10 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Adipotide is the name associated with an experimental peptidomimetic designed to target the vasculature of white adipose tissue and deliver a proapoptotic component. It is also discussed as prohibitin-targeting peptide 1. This is a different strategy from receptor-mediated appetite regulation or NNMT inhibition with 5-Amino-1MQ.

What the research measured

Kolonin and colleagues reported targeted adipose-tissue experiments in mice in Nature Medicine in 2004. Barnhart and colleagues later published obese-monkey research in Science Translational Medicine in 2011. The findings concern controlled animal models, not an established human weight-management treatment. The primate work also documented renal-function and toxicity signals that are central to its interpretation.

Sporting claims and limitations

In physique discussions, direct targeting of fat can sound more specific than changing appetite. Biological targeting does not guarantee that other organs are protected, particularly where a compound or its components are processed. An animal response cannot establish a predictable cosmetic result, safe human exposure or improved exercise capacity. AOD9604 follows another research approach and cannot supply missing safety data for Adipotide.

Product identity and documentation

For the catalogue item, identity needs more than a short peptide name. Documentation should specify the targeting and active components, sequence-related characteristics and the actual batch tested. The selected quantity is a source label, not a regimen. A certificate of purity cannot remove the renal concerns identified in preclinical research or authenticate an unspecified supplier preparation.